Anzeige
Mehr »
Login
Samstag, 25.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
Hinter dem nuklearen Ansturm im Silicon Valley: Eine strategische Chance entsteht
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AGEB | ISIN: US7013543001 | Ticker-Symbol: N/A
1-Jahres-Chart
PARKERVISION INC Chart 1 Jahr
5-Tage-Chart
PARKERVISION INC 5-Tage-Chart
ACCESS Newswire
585 Leser
Artikel bewerten:
(2)

ParkerVision, Inc.: ParkerVision Receives Favorable Markman Rulings in Infringement Actions Against MediaTek and Realtek

Finanznachrichten News

JACKSONVILLE, FL / ACCESSWIRE / January 29, 2024 / ParkerVision, Inc. (OTCQB:PRKR) announced today that the United States District Court for the Western District of Texas issued its Markman, or claim construction, rulings in ParkerVision's patent infringement actions against MediaTek Inc. and MediaTek USA Inc. (collectively, "MediaTek") and Realtek Semiconductor Corp. ("Realtek"). The Court's claim constructions are largely favorable to ParkerVision.

The Court held back-to-back Markman hearings on Friday, January 26, 2024, for the MediaTek and Realtek actions. Consistent with its standard practice, the Court issued preliminary rulings on the disputed claim constructions in advance of the Markman hearings. The Markman hearings were then held to allow the parties to present arguments with regard to any of the Court's preliminary rulings that they wished the Court to reconsider and/or fine-tune.

In ParkerVision v. MediaTek, the Court adopted ParkerVision's proposed claim constructions for 13 of 16 disputed terms while adopting two proposed terms for MediaTek, and one term the Court construed on its own. In ParkerVision v. Realtek, the Court adopted ParkerVision's proposed claim constructions for nine of 10 disputed terms, with the one remaining term being a combination of the proposals from both parties.

These MediaTek and Realtek infringement actions were initially filed in November 2022 and allege infringement against both parties of the same four ParkerVision patents. Both cases are scheduled for jury trial in December 2024. The Company has inter partes review actions pending against one of the patents. In 2023, ParkerVision filed two additional infringement cases against MediaTek and one new infringement case against Realtek alleging infringement of different ParkerVision patents.

Jeffrey Parker, Chairman and Chief Executive Officer of ParkerVision stated, "We are pleased with the claim construction rulings and appreciate the continued efficiency of the Texas court system and the pace at which the Court has been moving our cases through the litigation process."

Parker continued, "Based on the Court's rulings on the disputed claim terms, we believe we are well positioned to guide a jury on how MediaTek and Realtek products infringe numerous ParkerVision patent claims, as well as why the asserted patents are not anticipated by prior art and therefore are not invalid. We look forward to the jury trials scheduled later this year."

About ParkerVision

ParkerVision, Inc. (OTCQB:PRKR) invents, develops, and licenses cutting edge, proprietary radio-frequency (RF) technologies that enable wireless solution providers to make and sell advanced wireless communication products. For more information, please visit www.parkervision.com.

Safe Harbor Statement
This press release contains forward-looking information. Readers are cautioned not to place undue reliance on any such forward-looking statements, each of which speaks only as of the date made. Such statements are subject to certain risks and uncertainties which are disclosed in the Company's SEC reports, including the Form 10-K for the year ended December 31, 2022, and Forms 10-Q for the quarters ended March 31, June 30, and September 30, 2023. These risks and uncertainties could cause actual results to differ materially from those currently anticipated or projected.

Contact:

Cindy French
Chief Financial Officer
cfrench@parkervision.com

Tony Vignieri
Communications Director
tvignieri@parkervision.com

SOURCE: ParkerVision, Inc.



View the original press release on accesswire.com

© 2024 ACCESS Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.